Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALS)
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Listed as NCT00696332, this PHASE2 trial focuses on ALS and remains completed. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States , Berlin, Germany , Bochum, Germany , Budapest, Hungary , Charlestown, United States , Kansas City, United States , Leuven, Belgium , Lissone (MI), Italy , London, Canada , Madrid, Spain and 14 more locations